Breaking News Instant updates and real-time market news.

VRX

Valeant

$21.80

-0.38 (-1.71%)

13:51
10/17/16
10/17
13:51
10/17/16
13:51

Valeant pricing strategy for Wellbutrin XL unsustainable, says Wells Fargo

Wells Fargo analyst David Maris said that, traditionally, brands facing the type of generic competition that Valeant's Wellbutrin XL faces see erosion in "the 90% range" and he wonders how the drug still shows growth despite having ten generic competitors. Maris concludes that the answer to that question is "pricing," and goes on to state that his review concludes that the company's pricing strategy for Wellbutrin XL is "unsustainable." The analyst maintains an Underperform rating on Valeant shares.

  • 16

    Nov

  • 14

    Dec

VRX Valeant
$21.80

-0.38 (-1.71%)

09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.
10/14/16
WELS
10/14/16
NO CHANGE
WELS
Underperform
Wells says Valeant price hikes a reaction to 'disappointing' prescription trends
Wells Fargo analyst David Maris noted Valeant's announcement earlier today that the company has decided to raise prices by 2% to 9% on a broad range of products. He believes the price increases are a result of the company taking "a sobering look at disappointing prescription trends" and continues to contend that consensus estimates for Valeant in 2017 are too high. The analyst, who has kept an Underperform rating on Valeant shares since starting coverage of the stock in February, said the company's "story is the same as it has been, and the only change is in how it is being told."

TODAY'S FREE FLY STORIES

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

I

Intelsat

$3.73

-0.08 (-2.10%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Intelsat reports Q1 EPS (29c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Under Armour reports Q1 EPS (1c), consensus (4c) »

Reports Q1 revenue…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
L3 Technologies raises FY17 EPS view to $8.50-$8.70 from $8.40-$8.60 »

FY17 consensus $8.60.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AB

AllianceBernstein

$22.75

-0.05 (-0.22%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
AllianceBernstein reports Q1 EPS 46c, consensus 44c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
WEX sees Q2 adjusted EPS $1.19-$1.26, consensus $1.30 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
Johnson Controls reports Q2 adj. EPS 49c, consensus 49c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
AstraZeneca confirms FY17 core EPS to decline low to mid teens percentage »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

WEX

WEX

$106.85

0.83 (0.78%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
WEX sees FY17 adjusted EPS $5.15-$5.50, consensus $5.33 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PSTB

Park Sterling Bank

$12.52

0.23 (1.87%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Park Sterling Bank »

Park Sterling Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

  • 25

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
L3 Technologies reports Q1 diluted cont ops EPS $2.07, consensus $1.81 »

Reports Q1 revenue $2.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
WEX reports Q1 adjusted EPS $1.23, consensus $1.22 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
AstraZeneca reports Q1 core EPS 99c vs. 95c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
Extended Stay lifts FY17 revenue view to $1.29B-$1.31B from $1.28B-$1.305B 

Consensus $1.3B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Hot Stocks
Breaking Hot Stocks news story on Nintendo »

Nintendo sees FY17 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$5.37

-0.06 (-1.11%)

06:53
04/27/17
04/27
06:53
04/27/17
06:53
Technical Analysis
Nokia trades sharply higher after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:53
04/27/17
04/27
06:53
04/27/17
06:53
Hot Stocks
Nintendo says Switch 'off to a promising start' »

Nintendo Switch, a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQGP

EQT GP

$26.75

-0.39 (-1.44%)

06:52
04/27/17
04/27
06:52
04/27/17
06:52
Hot Stocks
EQT GP increases quarterly distribution 8% to 19.1c per share »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    May

POL

PolyOne

$37.39

-0.02 (-0.05%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
PolyOne reports Q1 adjusted EPS 59c, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Extended Stay America reports Q1 adj. EPS 15c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

, GOOG

Alphabet

$871.73

-0.57 (-0.07%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Periodicals
Fiat Chrysler seeks more self-driving supplier partners, Reuters reports »

Fiat Chrysler (FCAU) is…

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

GOOG

Alphabet

$871.73

-0.57 (-0.07%)

GOOGL

Alphabet Class A

$889.14

0.3 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Nintendo reports FY16 profit per share Y853.87 vs. Y137.4 last year »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:50
04/27/17
04/27
06:50
04/27/17
06:50
General news
Front-month WTI crude prices are down 1% »

Front-month WTI crude…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.